Investigational agents for epithelial ovarian cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 5, 2005, Pages 855-868

  Muggia, Franco ^a   Kosloff, Rebecca ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Clinical trials; Epithelial ovarian cancer; Intraperitoneal therapy; Molecular therapy; Targeted drug therapy

Indexed keywords

AMD 743; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CA 125 ANTIGEN; CANFOSFAMIDE; CARBOPLATIN; CISPLATIN; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOTHILONE B; EPOTHILONE DERIVATIVE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLUTATHIONE TRANSFERASE; HALICHONDRIN B; LURTOTECAN; MG 114; OXALIPLATIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEMETREXED; SATRAPLATIN; TAXANE DERIVATIVE; TETRAPLATIN; TOPOTECAN; TRABECTEDIN; TRABECTIDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZD 0743;

ADVANCED CANCER; ALOPECIA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE TARGETING; GENE THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; NEUROTOXICITY; OVARY CANCER; REVIEW; SURGICAL TECHNIQUE; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 27744524661     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.5.855     Document Type: Review

References (105)

1. Karlan BY, Markman MA, Eifel PJ. Ovarian cancer, peritoneal carcinoma, and fallopian tube carcinoma. In: Cancer Principles and Practice of Oncology. Seventh Edition. Devita VT, Hellman S, Rosenberg SA (Eds). Lippincott Williams and Wilkins, PA, USA, 1364 (2005).
2. Chan JK, Manuel M, Osann K, Cheung MK. Progress and trends in ovarian cancer survival over the last 15 years. Society of Gynecologic Oncologists, 36th Annual Meeting. Abstract 72, (2005).
3. Muggia FM. Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132. Int. J. Gynecol. Cancer 13(Suppl.), 156-162 (2003).
4. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18(17), 1084-1092 (2000).
5. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95(17), 1320-1329 (2003).
6. Ozols RF, Bundy BN, Greer BE et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194-3200 (2003).
7. Calvert AH, Newell DR, Bumbrell EL et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7(11), 1748-1756 (1989).
8. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335(26), 1950-1955 (1996).
9. Markman M, Bundy BN, Alberts DS. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paditaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Co-operative Oncology Group. J. Clin. Oncol. 19(4), 1001-1007 (2001).
10. Armstrong DK, Bundy BN, Baergen R et al. Randomized Phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Proc. Am. Sec. Clin. Oncol. 21(Abstract), 803 (2002).
11. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl J. Med. 334(1), 1-6 (1996).
12. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cydophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92(9), 699-708 (2000).
13. Muggia FM. Recent updates in the clinical use of platinum compounds in the treatment of gynecologic cancers. Semin. Oncol. 31(S14), 17-24 (2004).
14. Gronlund BO, Hogdall C, Hilden J, Engelholm SA, Hogdall EVS, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J. Clin. Oncol. 22(20), 4051-4058 (2004).
15. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol. 9(7), 1138-1150 (1991).
16. Hakes TB, Chalas E, Hoskins WJ et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol. Oncol. 45(3), 284-289 (1992).
17. McGuire WP, Hoskins WJ, Brady MF et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 13(7), 1589-1599 (1995).
18. Gore M, Mainwaring P, A'Hern R et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J. Clin. Oncol. 16(7), 2426-2434 (1998).
19. Kristensen GB, Vergote I, Eisenhauer E et al. First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs. TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival. Proc. Am. Soc. Clin. Oncol. 22(14S), Abstract 5003 (2004).
20. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol 21(13), 2460-2465 (2003).
21. Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer 13(S2), 196-203 (2003).
22. Varia MA, Stehman FB, Bundy BN et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21(15), 2849-2855 (2003).
23. Seiden M, Benigno BB. A pivotal Phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG 1 murine monoclonal antibody) in epithelial ovarian cancer (EOC). Proc. Am. Soc. Clin. Oncol. 22(14S), Abstract 5008 (2004).
24. Cure H, Bay JO, Plagne R, Chollet P. Dauplat J. High-dose chemotherapy in advanced epithelial ovarian cancer. Bull. Cancer 88(9), 842-851 (2001).
25. Ledermann JA, Frickhofen N, Wandt H et al. on behalf of he EBMT and AGO/AIO. A Phase III randomised trial of sequential high dose chemotherapy (HDC with peripheral blood stem cell support or standard dose chemotherapy (SDC) for first-line treatment of ovarian cancer. Proc. Am. Soc. Clin. Oncol. 23(16S) (2005) (Abstract 5051).
26. Pellegrini F, Budman DR. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 23(3), 264-273 (2005).
27. Mani S, Macdaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. 10, 1289-1298 (2004).
28. 2 (level 2, L2) every 3 weeks: a Phase I study. Proc. Am. Soc. Clin. Oncol. 23(16S) (2005) (Abstract 5114).
29. Poole CJ, Thomas H, Gore M et al. Randomized Phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC). Proc. Am. Soc. Clin. Oncol. 23(16S) (2005) (Abstract 5017).
30. See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest. 22(2), 29-44 (2004).
31. McMeekin DS, Krasner C, Chan S et al. Final results of a Phase II study of weekly trabectedin in second/third line ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 23(16S) (2005) (Abstract 5011).
32. Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23(9), 1867-1874 (2005).
33. Spentzos D, Levine DA, Ramoni MF et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J. Clin. Oncol. 22(23), 4700-4109 (2004).
34. Halperin R, Pansky M, Vaknin Z, Zehavi S, Bukovsky I, Schneider D. Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 110(2), 207-210 (2003).
35. Freimann S, Ben-Ami I, Hirsh L, Dantes A, Halperin R, Amsterdam A. Drug development for ovarian hyper-stimulation and anticancer treatment: blocking of gonadotropin signaling for epiregulin and amphiregulin biosynthesis. Biochem. Pharmacol. 68(6), 989-996 (2004).
36. Ahlgren JD, Ellison NM, Gottlieb RJ et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive Phase II trials of the Mid-Atlantic Oncology program. J. Clin. Oncol. 11(10), 1957-1968 (1993).
37. Bowman A, Gabra H, Langdon SP et al. CA125 response is associated with estrogen receptor expression in a Phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 8(7), 2233-2239 (2002).
38. Papadimitriou CA, Markaki S, Siapkaras J et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a Phase II study. Oncology 66(2), 112-117 (2004).
39. Blank SV, Chang R, Muggia FM. Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer. Oncology 19(4), 553-622 (2005).
40. Bookman MA, Darcy KM. Clarke-Pearson D, Boothby RA, Horowitz JR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21(2), 283-290 (2003).
41. Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5051 (2005).
42. Aghajanian C, Sabbatini P. Derosa F et al. A Phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5047 (2005).
43. Vasey P, Kaye S, Paul J et al. A Phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers. Proc. Am. Soc. Clin. Oncol. 22(14S), Abstract 5017 (2004).
44. Blank SV, Curtin JP, Goldman NA et al. Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5052 (2005).
45. Schilder RJ, Kohn E, Sill MW, Lewandowski G, Lee RB, Decesare SL. Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer: Gynocology Oncology Group 170C. Proc. Am. Soc. Clin. Oncol. 22 (451), Abstract 1814 (2003).
46. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004).
47. Ransom M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br. J. Cancer 90(12), 2250-2255 (2004).
48. Baselga S, Hammond LA. HER-targeted tyrosine kinase inhibitors. Oncology 63(S1), 6-16 (2002).
49. Xia W, Mullin RJ, Keith BR et al. Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21(41), 6255-6263 (2002).
50. Burris HA, Taylor C, Jones S. A Phase I study of GW572016 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 22, Abstract 994 (2003).
51. Spector N, Raefsky E, Hurwitz H. Safety, clinical efficacy, and biologic assessements from EGF100004: a randomized Phase IB study of GW572016 for patients with metastatic carcinoma overexpresing EGFR or erbB2. Proc. Am. Soc. Clin. Oncol. 22, Abstract 772 (2003).
52. Hidalgo M, Ehrlichman C, Rowinsky E. Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 21, Abstract 65 (2002).
53. Campos SM, Seiden MV, Oza A et al. A Phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. Proc. Am. Soc. Clin. Oncol. 22(14S), Abstract 5054 (2004).
54. Garcia AA, Oza AM, Hirte H et al. Interim report of a Phase II clinical trial of bevacuzimab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian cancer (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5000 (2005).
55. Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) Study. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5009 (2005).
56. DuPont J, Schwartz L, Koutcher J et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. 22(14S), Abstract 3009 (2004).
57. Downs LS, Boente MP, Argenta P. Carson LF, Judson PL. Interim analysis of a prospective randomized trial of thalidomide with topotecan compared to topotecan alone in women with recurrent epithelial ovarian or primary peritoneal cancer. Cancer Invest. 23(S1), Abstract 36 (2005).
58. Rosano L, Spinella F, Salani DI et al. Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma. Cancer Res. 63(10), 2447-2453 (2003).
59. Witteveen PO, Los M, Groenewegen G, Voest E. A Phase I study of atrasentan in combination with liposomal doxorubicin in platinum resistant ovarian cancer. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 3170 (2005).
60. Schroder W, Witteveen E, Abadie S et al. A Phase IB. open label, safety and pharmokinetic (PK) study of escalating doses of PTK787/ZK 222584 in combination with paclitaxel and carboplatin in patients (PTs) with stage IIC to TV epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5042 (2005).
61. Motzer RJ, Rini BI, Michaelson MD et al. The SU11248 study group. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 4508 (2005).
62. Maki RG, Fletcher JA, Heinrich MC et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 9011(2005).
63. Schmandt RE, Broaddus R, Lu KH et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98(4), 758-764 (2003).
64. Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin. Cancer Res. 10(2), 681-690 (2004).
65. Aghajanian C, Dizon D, Yan XJ et al. Phase I trial of PS-341 and carboplatin in recurrent ovarian cancer. Proc. Am. Soc. Clin. Oncol. 21(1815), Abstract 452 (2003).
66. Armstrong DK, Blessing JA, Look KY, Schilder R, Nunez ER. A randomized Phase II evaluation of bryostatin-1 (NSC 339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study. Invest. New Drugs 21(3), 373-377 (2003).
67. Adjei AA, Croghan, GA, Erlichman C et al. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 9(7), 2520-2526 (2003).
68. Ratain MJ, Flaherty KT, Stadler WM et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a Phase II randomized discontinuation trial (RDT). Proc. Am. Soc. Clin. Oncol. 22(14S), Abstract 4501 (2004).
69. Hussain MM, Kotz H, Minasian L et al. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J. Clin. Oncol. 21(23), 4356-4363 (2003).
70. Muggia FM. Exploring the role of intraperitoneal (ip) drug therapy in ovarian cancer: overview of strategies. The Chemotherapy Foundation Symposium (2005).
71. Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer 13(S2), 196-203 (2003).
72. Balkwill F, Schlom J, Berek J et al. Discussion: immunological therapeutics in ovarian cancer. Gynecol. Oncol. 88, S110-S1113 (2003).
73. Windbichler GH, Hausmaninger H, Stummvoll W et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized Phase III trial. Br. J. Cancer. 82(6), 1138-1144 (2000).
74. Apte S, Vadhan-Raj S, Cohen L et al. Hematopoietic, immunomodulatory, antitumor, and toxicity profiles of sequential GM-CSF and IFN-γ1b biotherapy and carboplatin in recurrent ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5053 (2005).
75. Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20(11), 2624-2632 (2002).
76. Wagner U, Kohler S, Reinartz S et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See the biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res. 7(5), 1154-1162 (2001).
77. Hilpert F, Harter P, Reinartz S et al. Phase I/II study of the anti-idiotypic monoclonal antibody ACA125 in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5018 (2005).
78. Method MW, Gordon AN, Finkler N, Cieszynski J, Nicodemus C. Final analysis of a randomized dosing study of oregovomab in patients with advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 5035 (2005).
79. van Zanten-Przybysz I, Molthoff C, Gebbinck JK et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOV18 in ovarian cancer patients: a pilot study. J. Cancer Res. Clin. Oncol. 128(9), 484-492 (2002).
80. Nicholson S, Gooden CS, Hird V et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol. Rep. 5(1), 223-226 (1998).
81. Mobus VJ, Baum RP, Bolle M et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am. J. Obstet. Gynecol. 189(1), 28-36 (2003).
82. Qian F, Gnjatic S, Jager E et al. Th1/Th2 CD4+ T-cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun. 4, 12-21 (2004).
83. As announced by a press release from Biomira and Merck KgaA (sponsors) on June 16 (2003).
84. Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Curr. Opin. Obstet. Gynecol. 16(1), 87-92 (2004).
85. Duan Z, Duan Y, Lamendola DE et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer Res. 9(7), 2778-2785 (2003).
86. Seelenmeyer C, Wegehingel S, Lechner J, Nickel W. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J. Cell. Sci. 116(Pt 7), 1305-1318 (2003).
87. Breidenbach M, Rein DT, Everts M et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 12(2), 87-193 (2005).
88. Cannistra, SA. Cancer of the ovary. N. Engl J. Med. 351(24), 2519-2529 (2004).
89. Stalsberg H, Abeler V, Blom GP, Bostad L, Skarland E, Westgaard G. Observer variation in histologic classification of malignant and borderline ovarian tumors. Hum. Pathol. 19(9), 1030-1035 (1988).
90. Baak JP, Chan KK, Stolk JG, Kenemans P. Prognostic factors in borderline and invasive ovarian tumors of the common epithelial type. Pathol. Res. Pract. 182(6), 755-774 (1987).
91. Bertelsen K, Holund B, Andersen JE, Nielsen K, Stroyer I, Ladehoff P. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int. J. Gynecol. Cancer. 3(4), 211-218 (1993).
92. Havrilesky L, Darcy M, Hamdan H et al. A Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21(20), 3814-3825 (2003).
93. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J. Clin. Oncol. 22(6), 1040-1044 (2004).
94. Matsumoto K, Katsumata N, Andoh M et al. Efficacy of irinotecan in patients with platinum and taxane- resistant ovarian cancer. Proc. Am. Soc. Clin. Oncol. 22, Abstract 5035 (2003).
95. Singer G, Oldt R III, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serious carcinoma. J. Natl Cancer Inst. 95(6), 484-486 (2003).
96. Kurzrock R, Benjamin RS. Phase I clinical trials in Oncology N. Engl. J. Med. 352, 2451-2453 (2005).
97. Silver DF, Hempling RE, Piver MS. Repasky LA. Effects of IL-12 on human ovarian tumors engrafted into SCID mice. Gynecol. Oncol. 72(2), 154-160 (1992).
98. Seiden M, Burris H, Matulonis U et al. A Phase II Trial of EMD72000 (matuzumab), a humanized antiEGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 3151 (2005).
99. Roskos L, Lohner M, Osborn K et al. Low pharmacokinetic variability facilitates optimal dosing of ABX-EGF in cancer patients, Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 362 (2005).
100. Arends R, Yang B, Schwab G, Lockbaum P, Funelas C, Roskos L. Flexible Dosing Schedules of Panitumumab (ABX-EGF) in Cancer Patients. Proc. Am. Soc. Clin. Oncol. 23(16S), Abstract 3089 (2005).
101. Hwu W-J. Thalidomide and its novel immunomodulatory components in the treatment of metastatic melanoma. In: The Chemotherapy Foundation Symposium 2003. Cancer Invest. 22(S1), Abstract 55 (2004).
102. Burris HA, Lorusso P. Jones S et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. Proc. Am. Soc. Clin. Oncol. 22(14S), Abstract 2004 (2004).
103. Chu QS, Holen KD, Rowinsky EK et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc. Am. Soc. Clin. Oncol. 22(14S), Abstract 2078 (2004).
104. Hirte HW, Vergote IB. Jeffrey JR et al. An International Multicentre Phase III Study of BAY 12-9566 (BAY) Versus Placebo in Patients (pts) with Advanced Ovarian Cancer (OVCA) Responsive to Primary Surgery/Paclitaxel + Platinum Containing Chemotherapy (CT). Proc. Am. Soc. Clin. Oncol. Abstract 843 (2001).
105. Berek JS, Taylor PT, Gordon AN, Schultes BC, Whiteside TL, Nicodemus CF. Randomized placebo-controlled study of oregovomab (OV) for consolidation of clinical remission in pts with ovarian cancer (OC): Prolonged disease-free survival (DFS) in optimal chemosensitive pts. Proc. Am. Soc. Clin. Oncol. 22(451), Abstract 660 (2003).